Innogenetics grants GlaxoSmithKline Biologicals a license for use of HPV SPF10 genotyping technology in clinical studies on HPV
Cervical cancer is caused by persistent infection with HPV, and is the second most common cancer among women worldwide, with some 500,000 new cases and 250,000 deaths due to this disease each year. In Europe, there are approximately 50,000 new cases and 25,000 cervical cancer deaths reported annually, while in the US more than 11,000 new cases and 3,800 deaths are expected in 2008.
GSK has licensed Innogenetics' SPF10 primer technology in order to continue its current and future clinical and epidemiological studies in the context of further development of some of their prophylactic vaccines directed against HPV.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.